Aspire Biopharma Holdings, Inc. 8-KCurrent Reports (8-K / ad hoc)

MD&A

Item 7.01 Regulation FD Disclosure On August 19, 2026, the Company intends to distribute an investor presentation. A copy of the investor presentation is furnished hereto as Exhibit 99.1 and incorporated herein by reference.